The FDA has given its approval to Ely Lilly and Company's new Alzheimer's testing procedure called Amyvid. The test uses a radioactive ink that allows doctors to screen for a plaque in the brain that has been tied to Alzheimer's.
According to foxnews.com, when injected into the bloodstream the radioactive ink binds the to harmful plaque beta amyloid, which is then illuminated on a positron emission topography scan.
Lilly will sell the product through its Avid Radiopharmaceuticals Inc. brand and the brand's CEO Dr. Daniel Skovronsky says it will add a new tool for doctors to use in diagnosing the ailment:
"The approval of Amyvid offers physicians a tool that, in conjunction with other diagnostic evaluations, can provide information to help physicians evaluate their patients," he said in the company's statement from Friday.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.